---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-102625"
form_type: "8-K"
ticker: "CTOR"
cik: "0001851484"
company_name: "CITIUS ONCOLOGY, INC."
filed_at: "2025-10-27T23:59:59+00:00"
generated_at: "2026-05-17T02:13:23.219261+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Citius Oncology shareholders approve doubling of stock incentive plan shares to 30M

## Summary
- At Oct 27 annual meeting, shareholders elected Class I directors Myron Holubiak and Joel Mayersohn for three-year terms.
- Shareholders approved amendment to 2024 Omnibus Stock Incentive Plan, increasing authorized shares from 15M to 30M.
- Ratification of Wolf & Company as independent auditor for fiscal year ending Sep 30, 2025 passed with 77.7M votes in favor.
- Plan amendment doubles share pool for equity awards; approved by board Sep 19, 2025, now effective.

## SEC filing metadata
- accession: 0001213900-25-102625
- form_type: 8-K
- ticker: CTOR
- cik: 0001851484
- company_name: CITIUS ONCOLOGY, INC.
- filed_at: 2025-10-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1851484/000121390025102625/0001213900-25-102625-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851484/000121390025102625/ea026265801-8k_citiusonc.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-102625
- JSON: https://secwatch.observer/filing/0001213900-25-102625.json
- Plain text: https://secwatch.observer/filing/0001213900-25-102625.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.